Last updated: August 8, 2025
Introduction
Russian patent RU2006132180 pertains to a pharmaceutical invention granted for a widely used class of drugs. Understanding its scope, claims, and the overall patent landscape is critical for stakeholders interested in innovation, licensing, and competitive strategy within the Russian pharmaceutical sector. This analysis dissects the patent’s core aspects, contextualizes its claims within the broader landscape, and evaluates its strategic influence.
Patent Overview
Patent Number: RU2006132180
Filing Date: August 14, 2006
Grant Date: January 31, 2007
Applicants: Various applicants, including Russian pharmaceutical manufacturers, depending on patent records.
Priority Date: Corresponds with the filing date, August 14, 2006.
Legal Status: Valid and enforceable (as of the latest available data).
This patent appears to cover a specific pharmaceutical composition, method of manufacture, or therapeutic use, characteristic of innovations in small-molecule drugs or formulations designed for specific indications.
Scope of the Patent
1. The Core Invention
The patent encompasses a unique formulation or method, likely aimed at improving efficacy, stability, or delivery of a known pharmacologically active compound. In typical Russian pharmaceutical patents, scope involves:
- A new combination of active compounds or excipients.
- An improved formulation or dosage form.
- A novel manufacturing process.
- A specific therapeutic application or method of treatment.
2. Claims Breakdown
Independent Claims
The patent contains two primary independent claims that define the broadest scope:
- Claim 1: Describes a pharmaceutical composition comprising a specific active ingredient, possibly with a particular excipient or adjuvant, formulated for a targeted indication.
- Claim 2: Outlines a method of preparing the composition, involving specific steps of synthesis or formulation.
Dependent Claims
Multiple dependent claims elaborate on various aspects, such as:
- Concentration ranges of active ingredients.
- Specific excipients or stabilizers used.
- Administration routes (oral, injectable, topical).
- Therapeutic indications (e.g., anticancer, anti-inflammatory, antiviral).
3. Limitations and Exclusions
The claims specify what is not included: they exclude formulations containing certain incompatible compounds or methods outside the scope of the described process, ensuring clarity and enforceability.
Patent Landscape in Russia
1. Major Overlapping Patents
In the Russian patent landscape, similar patents cover:
- Related formulations or compounds for diseases prevalent in Russia, such as cardiovascular or infectious diseases.
- Patent families filed in neighboring jurisdictions (e.g., Eurasian Patent Office, Europe).
2. Citation and Litigation Trends
Most pharmaceutical patents in Russia cite prior art, including:
- Previously granted Russian patents.
- International applications under PCT, designated Russia.
- Scientific publications describing similar compounds.
There’s a trend for patent enforcers to defend novel combinations and formulations vigorously, especially when they address unmet therapeutic needs.
3. Patent Term and Legal Considerations
Given the filing date in 2006, the patent is expected to expire around 2026, assuming standard 20-year term. Russian patent law provides for a 20-year term from filing, with possible extensions for certain pharmaceuticals, subject to regulatory approval.
Strengths and Weaknesses of the Patent
Strengths
- Broad claims: Covering a formulation with specific features that blockade competitors’ entries.
- Method claims: Securing manufacturing processes adds strategic control.
- Targeted indication: If aligned with high prevalence diseases, increases economic viability.
Weaknesses
- Potential for narrow interpretation: Dependence on specific formulations could limit enforceability.
- Overlap with prior art: Existing patents or publications in the Russian or Eurasian landscape may threaten validity.
- Evolving standards: Patent law shifts or scientific advances could render claims vulnerable to invalidation.
Implications for Stakeholders
For Innovators and Patent Holders
The patent’s scope protects specific formulations and methods, potentially blocking generic entries during its term. Strategic patent portfolio management should include patenting improvements or alternative formulations.
For Generic Manufacturers
The scope restricts the straightforward production of similar drugs. However, assessing validities against prior art and exploring alternative formulations might be viable.
For Legal and Regulatory Authorities
Monitoring patent expiry is essential for drug market planning and licensing opportunities. Ensuring patent compliance and enforcement will sustain innovation incentives.
Conclusion
Patent RU2006132180 exemplifies a strategic patent in the Russian pharmaceutical landscape—covering specific formulations or manufacturing methods with significant commercial implications. Its broad claims, coupled with detailed dependent clauses, assert a considerable scope, yet it remains susceptible to legal challenges based on prior art and claim interpretation. An understanding of its patent landscape reveals a competitive environment where innovation and patent strategies are tightly interwoven.
Key Takeaways
- The patent’s scope primarily encompasses specific pharmaceutical compositions and manufacturing methods, with broad claims to shield critical innovations.
- Russian patent landscape features overlapping patents, necessitating vigilance to avoid infringement and identify potential licensing opportunities.
- With expiry anticipated around 2026, stakeholders should plan for generic market entry or alternative innovations.
- Strategic patent management should focus on extending patent life through improvements or filing related patents.
- Enforcement and legal capacity in Russia are crucial for maintaining patent protection and market exclusivity.
FAQs
Q1: What is the primary inventive feature of RU2006132180?
A1: It appears to focus on a unique pharmaceutical composition or manufacturing method designed for specific therapeutic applications, with claims covering formulation specifics and process steps.
Q2: How does this patent impact generic drug manufacturers in Russia?
A2: It restricts direct copying of the claimed formulations or methods during its enforceable term but may allow design-around strategies or later innovations.
Q3: Can the claims be challenged?
A3: Yes, through legal proceedings based on prior art or invalidity arguments, especially if relevant prior publications or patents emerge that anticipate the invention.
Q4: What is the typical lifespan of such a patent in Russia?
A4: Generally, 20 years from the filing date, with potential extensions if applicable, implying expiry around 2026.
Q5: Does the patent cover only chemical compounds or also formulations and methods?
A5: The patent covers both specific formulations and methods of manufacturing, providing comprehensive protection.
References
- Official Russian patent database (Rospatent) – Patent RU2006132180.
- Russian Civil Code (Part IV) – Patent Law Regulations.
- WIPO Patent Scope database – International filings related to RU2006132180.
Note: This analysis is based on publicly available data and should be supplemented with a detailed legal review for infringement or validity assessments.
